OOTW ORACLE BRIEF — 24 April 2026

The psychedelic intelligence feed is quiet this morning in one specific sense: MiroFish's eight-agent simulation returned no discrete predictions from its overnight run. That silence is itself a signal worth reading carefully.

When a swarm engine processing 387 signals declines to crystallise any high-confidence forecasts, it typically means one of three things: the landscape is at an inflection point where evidence pulls in contradictory directions; the dominant narratives are approaching resolution and the next move is genuinely binary; or the market has already priced in the most legible outcomes. On current evidence, all three conditions appear to hold simultaneously.

The ibogaine-veteran thread, running at full narrative saturation, reflects a situation where legislative and clinical momentum have outpaced the regulatory machinery. The Stanford observational data on ibogaine's efficacy in combat veterans with TBI-associated PTSD continues to circulate as the de facto evidentiary anchor for congressional advocates, yet the DEA's scheduling posture on ibogaine remains the decisive chokepoint. Until the agency signals a formal review timeline, the narrative thread generates heat without producing a tradeable event. The prediction engine is correct to withhold a forecast here — there is no near-term catalyst with a legible date attached.

MDMA's FDA trajectory presents a different kind of uncertainty. Following the June 2024 advisory committee rejection and the subsequent complete response letter to Lykos Therapeutics, the field has been in a period of structured waiting. Lykos's resubmission strategy, the scope of any additional Phase 3 requirements, and the broader question of whether MAPS's therapy model survives commercial restructuring are all unresolved. The 80% narrative heat score reflects ongoing press attention, not clinical or regulatory progress. The oracle notes that a resubmission decision — or a formal abandonment — remains the single most consequential near-term binary in the sector.

Market signals add texture to this picture. COMPASS Pathways moving +4.7% on a day when ATAI retreats -2.9% and MMED falls -3.1% suggests selective rotation toward late-stage clinical assets with cleaner regulatory profiles. COMPASS's COMP360 psilocybin program, having reported Phase 2b data, is perceived as carrying lower near-term binary risk than the MDMA complex or early-stage platforms. That premium is rational, though it assumes the FDA's current appetite for psychedelic-assisted therapy review — never fully predictable — holds steady.

The federal rescheduling thread, at 83% narrative heat, deserves particular caution. Congressional activity around Schedule I reform is real but diffuse; multiple overlapping bills address cannabis, psilocybin, and ibogaine under different frameworks and with different coalition architectures. The oracle's consistent position is that federal rescheduling for classical psychedelics remains a 2027-at-earliest story absent an executive intervention that currently has no clear champion inside the administration.

What MiroFish's silence communicates, in aggregate, is that the psychedelic ecosystem is in a transitional holding pattern — past the era of pure clinical optimism, not yet arrived at durable commercial or regulatory resolution. The entities generating the most search and media heat (ketamine, MDMA, psilocybin, ibogaine) are all caught between demonstrable clinical signal and unresolved institutional friction.

The oracle will be watching for three near-term triggers: any DEA scheduling notice touching ibogaine; a Lykos resubmission announcement or formal withdrawal; and any COMPASS Phase 3 design disclosure. Until one of those surfaces, the swarm's restraint is the most honest forecast available.